Status: Recruiting
Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study
The study is a multicenter, randomized controlled, phase III clinical study, and the purpose of the study is to explore the complete response rate (CR, Defined as pathological complete response (pCR) + Clinical complete response (cCR) sustained for over one year) of patients with locally advanced rectal cancer(LARC) treated with personalized long-course radiotherapy plus chemotherapy with or without Serplulimab. A total of 184 patients were included in this study.
Participants needed: 184
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: West China HospitalUpdated: Jun 13, 2025Locations: 1
Eligibility criteria
Age: ≥18 years old; sex is not limited. [+10]
Patients who have previously received pelvic radiotherapy. [+7]